Cancer is not a single disease. Many targeted drugs only work in a small fraction of patient population, sometimes across seemingly unrelated cancer types. In order to achieve the necessary statistical power to cover most of cancer types, it is necessary to screen candidate compounds on 300-500 cancer cell lines to:

• Identify cancer indication
• Identify sub-population of highly sensitive cancer genotypes to generate patient stratification hypothesis

We have collected over 300 cancer cell lines, as well as our proprietary primary cancer cells which are backed by detailed patient clinical information and extensive cDNA microarray data. The Omni Panel will provide the most comprehensive analysis of lead compound in vitro, and important resource for predictive biomarker discovery.